Is Datopotamab currently on the market?

Datopotamab (Datopotamab) is a TROP2-targeted antibody drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo. Its commercial name is "Datroway". The global launch of the drug has been rapid and highly anticipated. According to the latest data in 2025, dabrotuzumab has been approved for marketing simultaneously in the United States, the European Union and China, becoming another important new drug that represents the direction of precision treatment of the TROP2 pathway after emtrastuzumab.

In terms of time, the U.S. Food and Drug Administration (FDA) officially approved the marketing of dabrotuzumab in January 2025 for the treatment of patients with EGFR-mutated non-small cell lung cancer and hormone receptor-positive, HER2-negative breast cancer. The European Medicines Agency (EMA) subsequently passed the review in April 2025, and China's National Medical Products Administration (NMPA) also approved the drug for marketing in August 2025, showing a trend of international synchronized approvals. The domestic version is also named "Dazhuoyou" and is currently in use in some urban hospitals.

Dedabrotuzumab has aroused widespread response in the market after its launch. Its breakthrough mechanism and relatively good safety profile have quickly made it a key topic of discussion in multiple oncology expert societies. In the U.S. market, the prescription volume of dabrotuzumab has increased significantly, especially in the field of breast cancer, and patient accessibility has been further improved. In China, although it has not yet been included in medical insurance, as one of the "imported drugs in urgent clinical need", it may be used in compliance with regulations in some specially approved hospitals.

The launch of dabrotuzumab not only completes the drug landscape of TROP2 targeted therapy, but also promotes the development of ADC drugs in precision tumor treatment. In the future, as the production technology matures and medical insurance negotiations advance, its price is expected to gradually decrease, benefiting more patients. The positive feedback from clinical to market shows that the launch of dedabrotuzumab will be an important turning point in the field of targeted tumor therapy.

Reference materials:https://www.google.com.hk/